The novel regulatory mechanism of METTL3- and METTL14-mediated epigenetic modification indicates potential targets in cancer immunotherapy.227 Recently, new evidence regarding the regulation of the TME by METTL3-mediated m6A modification in CRC has been found. The gene discussed is METTL3; the disease is cancer.